NCT06313437 - Revumenib in Combination With 7+3 + Midostaurin in AML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

March 2, 2026

Study Completion Date

March 2, 2027

Conditions

Acute Myeloid LeukemiaAML, AdultAML With Gene MutationsAMLLeukemia

Interventions

DRUG

Revumenib

Menin inhibitor, 25 and 113 mg capsules, taken orally per protocol.

DRUG

Midostaurin

Kinase inhibitor, capsule taken orally per protocol.

DRUG

Cytarabine

Antineoplastic agent, via intravenous (into the vein) infusion per protocol.

DRUG

Daunorubicin

Antineoplastic agent, via intravenous (into the vein) infusion per protocol.

Trial Locations (2)

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston